Psychometric properties of the painDETECT questionnaire in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis:Rasch analysis and test-retest reliability by Rifbjerg-Madsen, Signe et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
Psychometric properties of the painDETECT questionnaire in rheumatoid arthritis,
psoriatic arthritis and spondyloarthritis
Rifbjerg-Madsen, Signe; Wæhrens, Eva Ejlersen; Danneskiold-Samsøe, Bente; Amris,
Kirstine
Published in:
Health and Quality of Life Outcomes
DOI:
10.1186/s12955-017-0681-1
Publication date:
2017
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY
Citation for published version (APA):
Rifbjerg-Madsen, S., Wæhrens, E. E., Danneskiold-Samsøe, B., & Amris, K. (2017). Psychometric properties of
the painDETECT questionnaire in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: Rasch analysis
and test-retest reliability. Health and Quality of Life Outcomes, 15, [110]. https://doi.org/10.1186/s12955-017-
0681-1
Download date: 03. Feb. 2020
RESEARCH Open Access
Psychometric properties of the painDETECT
questionnaire in rheumatoid arthritis,
psoriatic arthritis and spondyloarthritis:
Rasch analysis and test-retest reliability
Signe Rifbjerg-Madsen1* , Eva Ejlersen Wæhrens1,2, Bente Danneskiold-Samsøe1 and Kirstine Amris1,3
Abstract
Background: Pain is inherent in rheumatoid arthritis (RA), psoriatic arthritis (PsA) and spondyloarthritis (SpA) and
traditionally considered to be of nociceptive origin. Emerging data suggest a potential role of augmented central
pain mechanisms in subsets of patients, thus, valid instruments that can identify underlying pain mechanisms are
needed. The painDETECT questionnaire (PDQ) was originally designed to differentiate between pain phenotypes.
The objectives were to evaluate the psychometric properties of the PDQ in patients with inflammatory arthritis by
applying Rasch analysis and to explore the reliability of pain classification by test-retest.
Methods: For the Rasch analysis 900 questionnaires from patients with RA, PsA and SpA (300 per diagnosis) were
extracted from ‘the DANBIO painDETECT study’. The analysis was directed at the seven items assessing somatosensory
symptoms and included: 1) the performance of the six-category Likert scale; 2) whether a unidimensional construct
was defined; 3) the reliability and precision of estimates. Another group of 30 patients diagnosed with RA, PsA or SpA
participated in a test-retest study. Intraclass Correlation Coefficients (ICC) and classification consistency were calculated.
Results: The Rasch analysis revealed: (1) Acceptable psychometric rating scale properties; the frequency distribution
peaked in category 0 except for item 5, threshold calibration >10 observations per category, no disorder in
the category measures for all items, scale category outfit Mnsq <2.0, small distances (<1.4 logits) between
thresholds for category 1, 2 and 3 for all items. (2) The principal component analysis supported unidimensionality; the
standardized residuals showed that 53.7% of total variance was explained by the measure and the magnitude of first
contrast had an eigenvalue of 1.5, no misfitting items, clinical insignificant different item hierarchies across diagnoses
(DIF < 0.5 logits). (3) A targeted item-person map, person and item separation indices of 1.88(reliability = 0.78),
and 13.04 (reliability = 0.99). The test-retest revealed: ICC: RA 0.86(0.56–0.96), PsA 0.96(0.74–0.99), SpA 0.93(0.76–98),
overall 0.94(0.84–0.98). Classification consistency was: RA 70%, PsA 80%, SpA 90%, overall 80%.
Conclusion: The results support that the PDQ can be used as a classification instrument and assist identification of
underlying pain-mechanisms in patients suffering from inflammatory arthritis.
Keywords: Inflammatory arthritis, Psychometrics, Rasch analysis, Test-retest reliability, PainDETECT questionnaire, Pain,
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Background
Rheumatoid arthritis (RA), psoriatic arthritis (PsA) and
spondyloarthritis (SpA) are considered systemic inflam-
matory rheumatic diseases that cause joint destruction,
disability and pain. The traditional approach to pain
management has focused on treatment of the underlying
disease using anti-inflammatory, disease-modifying drugs
[1, 2]. However, in some patients, pain does not improve
despite seemingly good inflammatory control [3–7]. This
suggests that although peripheral tissue inflammation
significantly contributes to nociceptive pain generation
in inflammatory arthritis [8], augmented central pain-
processing may play a prominent role in persistent
pain [6].Thus, there is a need for instruments that
can assist in identifying patients with augmented
central pain mechanisms and thereby help tailor an
effective, individualised treatment.
To the best of our knowledge no instruments have
been developed specifically to assist in mechanisms-
based pain classification of patients with inflammatory
joint disorders. The painDETECT questionnaire (PDQ)
is a symptom-based assessment tool developed to assist
identification of neuropathic pain [9]. It assigns a score
to the patients, which classifies pain into three groups:
neuropathic, unclear or non-neuropathic (nociceptive)
pain. Neuropathic pain is characterized by allodynia,
hyperalgesia, dysesthesia and sudden pain; somatosen-
sory symptoms assessed by the PDQ [10]. Emerging
evidence supports that there are striking pain phenotypic
similarities between neuropathic pain and pain condi-
tions characterised by augmented central pain process-
ing; that is how patients express their symptoms of
abnormal sensory perceptions and the quality of their
pain [11]. Based on this overlap, the PDQ has been used
as indicator of augmented central pain processing in
patients with osteoarthritis and fibromyalgia [12–15]
and recently, the PDQ has been introduced in studies of
pain mechanisms in patients with RA [16, 17] and SpA
[18]. Satisfactory psychometric properties of the PDQ
have been demonstrated within osteoarthritis [19]. How-
ever, they remain to be evaluated within inflammatory
arthritis and it is well-established that the psychometric
properties of a questionnaire may vary depending on the
population it is used in [20]. Because the PDQ is gaining
ground as pain phenotyping instrument within these
diagnoses, the psychometric properties, should be inves-
tigated as a prerequisite to implementing the PDQ in
clinical research or daily practice, in order to secure
valid and reliable pain classification of these particular
patients. Rasch analysis allows detailed analyses of an
instruments’ rating scale structure and measurement
properties and as such it also gives important informa-
tion for evaluation of the trichotomous classification
system of the PDQ. Rasch analysis has traditionally been
applied to questionnaires to evaluate a hierarchy of the
items e.g. in the SF-36 [21], but it has also been shown
to be useful in questionnaires where the items are
equally descriptive of the condition as in the PDQ [22].
Furthermore, Rasch analysis includes a mathematical
reliability measure describing how well an instrument
differentiates between groups; patients with different
pain phenotypes. Finally, large variation in the examined
population e.g. with regard to disease severity and
gender can ensure generalisability [23].
Whether an instrument has reliable classification
ability, can be further investigated by test-retest, which
will give an estimation of the stability [20]. Pain pheno-
types are as such not expected to alter, thus the classifica-
tion thereof should be consistent. Estimation of intraclass
correlation coefficients based on exact scores can further
support reliablity.
The overall purpose of this study was to evaluate the
psychometric properties of the PDQ in patients with
inflammatory joint disease (RA, PsA, SpA). Specifically,
to conduct Rasch analysis, including reliability analysis
of pain classification by means of person and item
distinction in a sample of patients representing all diag-
noses, both genders and every degree of activity of the
disease. Further, to explore the agreement of scores and
the stability of pain classification by test-retest.
Methods
Study design and setting
The Danish DANBIO-registry is a nationwide rheumato-
logic clinical quality registry, which covers >90% of
adults treated with biologics due to rheumatic disease
[24]. The registry also includes data on patients treated
with synthetic disease-modifying antirheumatic drugs
(DMARDs). Before routine clinical control of the arthritic
condition, the patients regularly complete diagnosis spe-
cific patient reported outcomes on the DANBIO touch
screens in the doctors waiting room. The rheumatologist
registers corresponding objective clinical outcomes, hence
common rheumatologic disease activity measures such as
the disease activity score-28 joints (DAS28) [25, 26] and
ankylosing spondylitis disease activity score (ASDAS) [27]
are available. These scores are composite scores including
subjective and objective parameters of level of inflamma-
tory activity and global health and thus describe the
current degree of activity of the specific disease.
Data for the Rasch analysis was acquired from
‘The DANBIO painDETECT study’ (in review), which
was a cross-sectional survey describing the prevalence of
pain phenotypes among patients with inflammatory
arthritis in Denmark. After feasibility was demonstrated
during a piloting period of a month at Frederiksberg Hos-
pital, an electronic version of the PDQ was implemented
nationwide on the DANBIO touch screens for 6 months
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(1 Dec 2013–1 June 2014). The test-retest study took place
at the Department of Rheumatology, Frederiksberg
Hospital, where patients with the diagnoses RA, PsA or
SpA registered in DANBIO were randomly invited to
complete the PDQ twice on the DANBIO touch screens in
connection with a clinical control. Based on clinical opin-
ion the retest should take place within ≥1 and <5 days after
the first completion in order to reduce the influence of
change in the underlying disease (ongoing peripheral
inflammation) [20].
Participants
To be eligible for inclusion in the Rasch analysis the
PDQ had to be complete and originate from a patient
who had a disease activity score registered on the same
day as the questionnaire was completed. Given the very
large sample, we were able to include questionnaires
from patients with different degrees of disease activity.
Seeking to ensure generalizability, it was decided that:
1) the extraction of questionnaires should be stratified
in thirds according to three disease activity categories
(low, moderate and high) defined by DAS28 or ASDAS,
and 2) there should be an equal distribution of gender
within the single diagnosis and disease activity category.
Finally, patients with PsA may suffer from either periph-
eral and/or axial involvement [28], hence both DAS28 and
ASDAS were accepted as disease activity scores. In cases
where both scores were reported, the highest score
defined the disease activity category.
These criteria restricted the sample, primarily be-
cause of the relatively low number of patients having
a high disease activity score (53 women with SpA had
a high ASDAS), which led to the final extraction pro-
cedure: for each diagnosis within each disease activity
category, complete questionnaires from the first 50
female respondents and the first 50 male respondents
were included.
In all, a sample of 900 questionnaires from 300 partici-
pants with either of the diagnoses (RA, PsA, SpA) and
450 of each gender was compiled. Still, this high number
is considered more than sufficient to obtain stable item
calibrations in defined subgroups (diagnosis/disease,
activity category/gender) with 99% confidence, given
good targeting [29].
In the test-retest study, the sample size calculation for
the Intraclass correlation coefficient (ICC) was based on
the assumption that the observed ICC value across all diag-
noses would be ≥0.95 [30], also aiming at a confidence
interval narrow enough for the lower 95% confidence limit
to be above >0.80. With 10 participants, the 95% CI around
an ICC of 0.95 would correspond to 0.83–0.99. Accord-
ingly, the inclusion for the test-retest study was open until
10 patients with each of the diagnoses RA, SpA or PsA had
completed the painDETECT twice with no missing data.
Patient’s disease activity was scored on the test-day.
The painDETECT questionnaire (PDQ)
The PDQ was originally developed and validated for pain
classification purposes [9] and has been translated into
several languages, including Danish (www.pfizerpatientre-
portedoutcomes.com). The PDQ comprises 12 items. The
first three assess current pain, strongest pain during the
past 4 weeks, and average pain during the past 4 weeks on
a 0–10 point numerical rating scale from “none” to “worst
imaginable”. The fourth item includes a chart representa-
tion of four pain course patterns depicting persistence,
fluctuation and attacks; the patients have to choose the
one resembling their pain pattern the most. The fifth item
display a mannequin on which the patients mark their
area of pain and pain radiation also responding to a yes/
no question about the presence of radiating pain. The
remaining seven questions regarding the presence and
severity of somatosensory signs and symptoms are rated
on a six-category Likert scale (from never (0) to very
strongly (5)): (1) burning sensation in the painful areas, 2)
tingling or prickling in areas of pain, 3) light touching is
painful, 4) sudden pain attacks in areas of pain, 5) cold or
heat is occasionally painful, 6) numbness in the painful
areas, 7) slight pressure triggers pain) [9, 14]. For diagnos-
tic purposes, a validated algorithm is used to calculate a
total score ranging from −1 to 38. Pain intensity ratings
are not included in the total score. The selection of one of
four pain course patterns contributes to the total score
with a value ranging from −1 to 1; the absence/presence
of radiating pain with a value of 0 or 2; and the presence
and severity of evaluated somatosensory signs and symp-
toms with a value ranging from 0 to 35. The resulting total
score classifies pain into three groups: a score > 18 indi-
cates that the presence of a predominant neuropathic pain
component is likely, a score of 13 to 18 is considered
uncertain, and a score < 13 indicates that a neuropathic
pain component is not likely present [9]. Used for classifi-
cation purposes, the PDQ has a sensitivity and specificity
of 84% (electronic version) in a mixed chronic pain popu-
lation using clinician-assessed diagnosis of pain mechan-
ism as a criterion based validity index [9].
Statistics
Baseline characteristics
Group differences were calculated using the non-
parametric Kruskal-Wallis test for ordinal and interval
variables and Chi-square test (n < 5; Fisher’s exact
test) for categorical variables. SAS software (version
9.3; SAS Institute Inc., Cary; North Carolina, USA)
was used for the statistical analyses.
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Rasch analysis
Seven of the nine PDQ questions which contribute to the
scoring algorithm were included in the Rasch analysis.
This was because: 1) the majority of points achievable on
the scoring algorithm, 35 out of 38, originate from these
questions, and 2) the scoring of the remaining two
elements of the PDQ does not have a character applicable
to Rasch analysis [19]. The item that assesses pain course
consists of four different patterns. A score of −1 is
assigned to one of the patterns, 0 to another and finally 1
to the remaining two. The item of presence of pain radi-
ation is dichotomous and has a score of either 0 or 2.
Thus, neither of the scorings of these two items can logic-
ally be converted into an ordinal scale. This was not taken
into consideration in the original development of the
questionnaire as Rasch analysis was not performed [9].
Furthermore, it has been demonstrated by Moreton et al.
[19] that these items perform less satisfactorily in Rasch
analysis. The Rasch analysis was carried out applying the
Rasch computer program WINSTEPS 3.90.0 [31]. Statis-
tics evaluating aspects of validity and reliability were
generated, including fit of the data to the Rasch model
assertions [23, 32]. The measures of severity of neuro-
pathic pain symptoms and the item difficulty measures
are expressed in logits (log-odds probability units) [33].
Rasch analysis procedures have been described in detail
elsewhere [23, 32, 34], hence our description of the Rasch
method used is brief.
The analyses were undertaken to assess: first, the
performance of the six-category Likert scale (rating scale
properties); second, whether the seven items defined a
unidimensional construct ‘neuropathic pain’ (unidimen-
sionality); third, the reliability and precision of pain classifi-
cation by the seven items (precision and reproducibility).
It was decided that the partial credit model (PCM)
[35] would be used should the data not fulfil the criteria
for the rating scale model (RSM). Both models are used
with polytomous data (i.e. data derived from response
scales with more than two categories). The PCM assumes
that the distance is not the same between different
response categories.
Based on Linacre’s guidelines [36, 37], the performance
of the Likert scale was addressed with a rating scale analysis
initially per diagnosis, followed by an analysis including all
diagnoses. Five properties were examined; the frequency
distributions, threshold calibration (<10 observations per
category), monotonic increase in category measures, scale
category outfit (Mnsq), and order of thresholds.
Analysis of dependency was based on correlation
statistics that was interpreted as follows: correlation > 0.7
high local dependency, <0.4 low local dependency [34].
To address whether the seven somatosensory items of
the PDQ defined a unidimensional construct (i.e. neuro-
pathic pain), a principal component analysis (PCA) of
the standardised residuals was performed and the
item and person goodness-of-fit statistics were exam-
ined [38, 39]. When analysing goodness of fit, under-
fit and overfit to the Rasch model were evaluated to
identify poorly fitting items that needed removal [23].
Also infit and outfit statistics were taken into consid-
eration [23]. Critical values for mean squares were
calculated based on the sample sizes for the separate
diagnosis (infit MnSq = 1.12, outfit MnSq = 1.35,
ZSTD < 2) and overall (infit MnSq =1.06, outfit MnSq
S = 1.2, ZSTD < 2) respectively [40]. Subsequently, an
evaluation of differential item functioning (DIF) was
performed investigating diagnosis, gender and disease
activity separately. DIF occurs when the item difficulty
estimates vary between groups and items exhibiting DIF
therefore, may represent a threat to unidimensionality.
Additionally, the hierarchical order of item difficulties
across diagnoses was explored.
The precision and reproducibility of the item diffi-
culty estimates and the neuropathic pain severity
measures were evaluated by the overall separation
and reliability indices. To obtain a desired reliability
coefficient of 0.80 for replicability of person and item
ordering [23], the separation indices must be at least
2.0, and the reliability index should be as close as
possible to 1.0 (range 0.0–1.0) [41]. Further, the item-
person map showing the threshold distribution of
items and persons respectively was assessed. Match of
the range of the two distributions was considered
good targeting.
Test-retest reliability
The PDQ was originally designed as a classification tool,
and not intended for outcome measurement, thus, the
primary statistical analysis for test–retest reliability was
based on Intraclass correlation coefficient (ICC) statis-
tics (absolute agreement) [42]. IBM SPSS Statistics 19
software was used for these analyses. A priori, the inter-
pretation of the results was defined as follows: values
greater than 0.7 represent acceptable agreement, while
values greater than 0.8 represent strong agreement and
greater than 0.9 very strong agreement [42]. Finally, the
classification consistency (i.e. proportion of no change in
pain phenotype) was calculated, as the PDQ originally
was designed as a classification tool.
Results
Study sample
In the original ‘DANBIO painDETECT study’ in all 15,978
patients were invited to participate in the survey. They
were registered as having any form of RA, PsA, SpA or
unspecific inflammatory arthritis (UA) (osteoarthritis not
included). In all, 7054 (44.2%) patients completed the
PDQ (RA; N = 3826. PsA; N = 1180. SpA; N = 1093. UA;
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N = 955), while 864 (5.4%) partially completed the PDQ,
6133 (38.4%) declined to participate, and 1927 (12.0%)
registered themselves as ‘pain-free’ (excluded).
Of the 7054 complete questionnaires, 4853 were
eligible for the Rasch analysis (RA; N = 3199. PsA;
N = 921. SpA; N = 723). Due to the strict inclusion
procedure the final sample was 900.
Baseline characteristics
Baseline characteristics of the Rasch sample are shown
in Table 1. Group differences were found across disease
activity categories within all diagnoses. Four differences
were found across diagnoses for the baseline test-retest
sample including age, disease duration, treatment with
DMARD and swollen joint count (Table 2).
Rating scale properties
The likelihood ratio test indicated lack of fit to an inter-
val model (RSM, p < 0.001). Accordingly, the analysis
was continued using the PCM [35]. Initially, the diag-
nostic groups were analysed separately, and subsequently
they were combined in one overall analysis. Only minor
differences were found between diagnoses; the analyses
revealed a frequency distribution that peaked in category
0 of the Likert scale except for item 5 (cold or heat is
occasionally painful), which peaked in category 4 for RA
and PsA, and category 3 for SpA. In the overall analysis,
the distribution for item 5 peaked in category 4. In the
diagnosis specific analysis, the threshold calibration
showed >10 observations per category except for
category 5 in items 3 (light touching is painful) and 4
(sudden pain attacks in areas of pain) for RA, in items 2
(tingling or prickling areas of pain), 3 and 4 for PsA, and
in items 2 and 4 for SpA. In the overall analysis >10
observations were found in all categories. Monotonic
increase of the category measures was found for all of
the items, both in the diagnosis specific and in the over-
all analysis. With the exception of item 4 in category 5
(few counts) for SpA, the scale category outfit revealed a
Mnsq <2.0, indicating no introduction of noise to the
measurement in any category. Threshold disordering
was found for items 1 (burning sensation in the painful
areas), 3, 4, 6 (numbness in the painful areas) and 7
(slight pressure triggers pain) for RA; items 6 and 7 for
PsA; item 2, 3 and 6 for SpA and items 2 and 6 in the
overall analysis. Small distances (less than 1.4 logits)
between thresholds were found in all analyses across all
items for categories 1, 2 and 3 (hardly noticed, slightly,
moderately) suggesting lack of distinction between
categories. Correlations did not indicate dependency
for the individual diagnoses or overall sample; RA
(0.09– -0.33), PsA (−0.03– -0.37), SpA (0.03– −0.35),
overall (−0.01– -0.35).
Unidimensionality
The PCA of the standardised residuals revealed that
57.5% (RA), 52.6% (PsA), 53.1% (PsA) and 53.7%
(overall) of the total variances were explained by the
measures, respectively and that the magnitude of first
contrast had an eigenvalue of 1.6 (RA, PsA, SpA) and
1.5 (overall) both supporting unidimensionality. Table
3 shows the fit statistics. Items 5 and 6 had mean
square values above the infit criteria across diagnoses.
DIF was observed within all areas tested; gender,
diagnosis and disease activity, however the DIF
contrasts were well below 0.5 logits [34]. Regarding
gender, the DIF was related to items 3 and 4, where
it was easier for men to obtain a high score, and
items 5 and 6 where it was easier for women to obtain a
high score. Furthermore, there was DIF across the three
diagnostic groups on items 1, 2, 4 and 7 as illustrated in
Fig. 1. This gives rise to different item hierarchies across
diagnoses as shown in Table 4, where diagnosis specific
item hierarchies based on item difficulty calibrations are
presented. In the current analyses, items with a positive
calibration were the most difficult (i.e. difficult to obtain a
high score; least endorsed), whereas items distributed at
the negative end of the scale were the easiest (i.e. easy to
obtain a high score; most endorsed). Item number 5 had
the same ranking in the hierarchy across all diagnoses
being the easiest item, whereas items number 2 and 4
were the two most difficult items. Finally, there was DIF
for disease activity for item 2 indicating that participants
with high disease activity reported higher scores with
regard to tingling or prickling in the painful areas.
Precision and reproducibility
The item-person distribution map, Fig. 2, illustrates that
the items and participants were targeted and only 3
participants had maximum scores, thus no actual ceiling
effect was observed. There was an indication of lack of
easier items to capture the persons with less severe
neuropathic pain symptoms. In the overall analysis
which showed similar results as the diagnosis specific
analyses, the person separation index was 1.88 (reliabil-
ity = 0.78), and the item separation index was found to
be 13.04 (reliability = 0.99).
Test-retest reliability
Complete data were obtained from thirty participants, ten
from each of the three diagnostic groups. The median
(IQR) response time between test and retest was 2.5 (2–3)
days. The median (IQR) PDQ ‘test’ scores were: RA
15(12–19), PsA 16 (7–27), SpA 7.5 (2–15), total 13.5 (7–19).
The median PDQ ‘retest’ scores were RA 13 (10–18),
PsA 13.5 (3–25), SpA 5.5 (1–15), total 11.5 (4–18).
Intraclass correlation coefficients (ICC) were: RA 0.86
(0.56–0.96), PsA 0.96 (0.74–0.99), SpA 0.93(0.76–98)
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Table 1 Baseline characteristics of the Rasch population stratified by disease activity level
low n moderate n high n p-value
RA
Age (yrs) 60(53.5–65) 100 61(53–68.5) 100 59(50–68.5) 100 0.84
Duration (yrs) 8(3–17) 93 5.5(2–14) 92 5(1–14) 92 0.03a
PDQ score 8(5–14) 100 12(7–18) 100 18(12–25) 100 <0.01
DMARD mono n (%) 65(74) 88 62(75) 83 54(70) 77 0.79
> 1 DMARD n (%) 23(26) 88 21(25) 83 23(30) 77 0.79
Biologics n (%) 38(38) 100 33(33) 100 31(31) 100 0.56
DAS28-crp 2.2(1.8–2.7) 100 3.9 (3.6–4.5) 100 5.7(5.4–6.25) 100 <0.01
TJC 28 0(0–1) 100 4(3–7.5) 100 13(9–18) 100 <0.01
SJC 28 0(0–0) 100 1(0–3) 100 5.5(2–9) 100 <0.01
VAS pain mm 25.5(13–41.5) 100 50(32.5–65) 100 75(57.5–86.5) 100 <0.01
VAS fatigue mm 29(18.5–56) 100 54(36.5–73.5) 100 77.5(57–92.5) 100 <0.01
VAS global mm 25.5(13.5–52.5) 100 58.5(41.5–74) 100 82.5(70.5–93.5) 100 <0.01
HAQ 0.5(0.125–1) 99 1(0.625–1.375) 99 1.75(1–2.25) 100 <0.01
Crp mg/l 3(1.5–5.5) 100 7(3–14) 100 23.5(11.5–39.5) 100 <0.01
IgM-RF n (%) 69(80) 86 64(79) 81 58(78) 74 0.96
Anti-CCP n (%) 31(54) 57 30(51) 59 19(42) 45 0.46
PsA
Age (yrs) 50.5(42–58) 100 52(41.5–60) 100 52(44–60) 100 0.56
Duration (yrs) 6(3–9) 91 4.5(1–9.5) 92 6(3–9) 87 0.30
PDQ score 9(5–12) 100 14(9–18) 100 19(14.5–24) 100 <0.01
DMARD mono n (%) 69 (95) 73 53(83) 64 54 (81) 67 0.04
> 1 DMARD n (%) 4(5) 73 11(17) 64 13(19) 67 0.04
Biologics n (%) 55(55) 100 44(44) 100 41(41) 100 0.11
DAS28-crp 1.8(1.6–2.35) 92 2.8(2.4–3.55) 92 4.4(3.8–5.1) 90 <0.01
TJC 28 0(0–1) 94 1(0–3.5) 92 5(2–12) 91 <0.01
SJC 28 0(0–0) 93 0(0–0) 92 0(0–2) 90 <0.01b
BASDAI (0–100) 21.5(13–28) 98 52(41–64) 98 77(71–85) 99 <0.01
BASFI (0–100) 15.5(7–27) 98 45.5(27–57) 98 74(62–86) 99 <0.01
ASDAS 1.5(1.1–1.8) 97 2.8(2.5–3.1) 97 4(3.7–4.5) 98 <0.01
VAS pain mm 20.5(12–30) 100 50(39.5–63) 100 77 (68–88.5) 100 <0.01
VAS fatigue mm 27(15–38) 100 65(48–77) 100 85(75–93) 100 <0.01
VAS global mm 22(14–30) 100 59.5(46–74) 100 85.5(77–94) 100 <0.01
HAQ 0.375(0–0.625) 96 0.75(0.51.25) 95 1.5(1–1.875) 96 <0.01
Crp mg/l 2(1–4) 100 3(1.5–6) 100 6(3–14) 100 <0.01
HLA-B27 n (%) 7(54) 13 10(53) 19 7(58) 12 0.95
SpA
Age (yrs) 45.5(36–53) 100 43.5 (35–52.5) 100 47(37–54) 100 0.52
Duration (yrs) 6(3–13) 94 4.5(2–9) 90 5(2–12) 89 0.14
PDQ score 8(5–13.5) 100 15(9–19.5) 100 17.5(10.5–22.5) 100 <0.01
DMARD mono n (%) 24(100) 24 21(84) 25 26(96) 27 0.06
> 1 DMARD n (%) 0 (0) 24 4(16) 25 1(4) 27 0.06
Biologics n (%) 78(78) 100 56(56) 100 54(54) 100 <0.01c
BASDAI (0–100) 22.5(14–34) 100 49(39–61) 100 72.5(65–83) 100 <0.01
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and total 0.94 (0.84–0.98). The Bland-Altman plots,
Fig. 3, illustrate the differences between test and
retest scores. The distribution of number of participants
in the three PDQ classification categories according to
diagnosis is reported in Table 5. Three, two and one
participant with RA, PsA and SpA, respectively, changed
classification group. This corresponded to a classification
consistency of pain phenotype of 70% within RA, 80%
within PsA, 90% within SpA, and 80% among participants
in total. Those participants who changed group, changed
between non-neuropathic and unclear (n = 1) or neuro-
pathic and unclear (n = 5), with only few points between
the first and second score.
Discussion
From the perspective of the Rasch model, the seven-item
version of the PDQ assessing somatosensory symptoms of
neuropathic pain demonstrated acceptable psychometric
properties across all three diagnoses (RA, PsA and SpA),
which was further supported by the test-retest analysis.
Current evidence suggests that both neuropathic pain
and pain conditions characterised primarily by augmented
central pain processing, e.g. fibromyalgia, may share simi-
lar neurobiological underpinnings [11]. Given that these
mechanisms give rise to clinical symptoms, it may be
expected that centrally mediated pain and neuropathic
pain share clinical features, which are captured by neuro-
pathic pain instruments based on somatosensory profiling
such as the PDQ. Thus, the objective of this study was to
investigate the psychometric properties of the PDQ when
applied in pain classification in patients with RA, PsA and
SpA. The study did not intend to evaluate construct valid-
ity, due to the lack of a clinically feasible and valid refer-
ence standard addressing this phenomenon.
The study showed overall acceptable rating scale prop-
erties of the PDQ supporting that the instrument may
be used in pain classification; assigning patients to one
of three categories based on a summed score and a vali-
dated algorithm. However, the rating scale analysis also
demonstrated a potential for collapsing Likert-scale
categories, as well as threshold disordering for items 2
and 6, in the overall analyses, which indicate that the
summed PDQ score should be used with caution to
grade the severity of neuropathic pain symptoms in
Table 1 Baseline characteristics of the Rasch population stratified by disease activity level (Continued)
BASFI (0–100) 16(10.5–31.5) 100 40.5(27–56) 100 67.5(49–83.5) 100 <0.01
ASDAS 1.7(1.3–1.90) 100 2.9(2.5–3.1) 100 4.1(3.8–4.5) 100 <0.01
VAS pain mm 21.5(12–35) 100 53.5(38–72) 100 75.5(65.5–86) 100 <0.01
VAS fatigue mm 31.5(17.5–48) 100 65(45.5–81) 100 83(71.5–92) 100 <0.01
VAS global mm 24.5(15.5–36) 100 61(46–78) 100 84(74–92) 100 <0.01
Crp mg/l 2(1–4) 100 3(2–7) 100 10(5–21) 100 <0.01
HLA-B27 n (%) 28(82) 34 20(63) 32 20(67) 30 0.17
Values are the median (interquartile range) or (n (%)). P-values are calculated by Kruskal-Wallis Test, Fishers exact test or Chi square. Except where indicated otherwise there
are difference/no difference across all groups according to p value. ano group difference between moderate – high disease activity p = 0.54, bno group difference between
low-moderate disease activity p = 0.31, cno group difference between moderate-high disease activity p = 0.78.DMARD Disease Modifying Anti-Rheumatic Drug, DAS28-crp
Disease Activity Score 28 –crp, TJC Tender Joint Count, SJC Swollen Joint Count, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BASFI Bath Ankylosing Spondylitis
Functional Index, ASDAS Ankylosing Spondylitis Disease Activity Score, VAS Visual Analogue Scale, HAQ Health Assessment Questionnaire, HLA-B27 Human Leucocyte
Antigen-B27, IgM-RF Immunoglobulin M Rheumatoid Factor, Anti-CCP Anti–citrullinated protein antibodies
Table 2 Baseline characteristics of the test-retest population
RA PsA SpA p-value
(n = 10) (n = 10) (n = 10)
Female sex n (%) 8 (80) 5 (50) 4 (40) 0.266
Age (years) 65 (62–68) 58.5 (49–67) 47 (32–52) 0.005a
Duration (years) 15.5 (8–24) 8.5 (5–14) 4 (2–6) 0.017b
DMARD n (%) 9 (90) 9 (90) 2(20) 0.003
Biologics n (%) 6 (60) 7 (70) 8(80) 0.879
DAS28-CRP 3.9 (3.7–4.2) 3.7 (3.1–4.4) - 0.519
TJC 28 5.5 (4–10) 6 (2–9) - 0.791
SJC 28 1 (1–4) 0 (0–0) - 0.020
BASDAI (0–100) - 67 (34–83) 28 (14–43) 0.364
BASFI (0–100) - 60.5 (37–89) 18 (13–32) 0.212
ASDAS - 3.05 (2.4–3.8) 2.1 (1.1–2.7) 0.104
VAS pain mm 43 (26–53) 61.5(25–73) 24.5 (19–41) 0.331
VAS fatigue mm 65 (40–79) 63.5 (32–82) 43 (26–67) 0.397
VAS global mm 50 (34–63) 72 (32–87) 29.5 (22–57) 0.219
HAQ 1.25 (0.875–2) - - -
Crp mg/l 5.5 (1–10) 4 (1–8) 3.5 (1–9) 0.939
HLA-B27 n (%) - 2(100)(n = 2) 3(75)(n = 4) 1
IgM-RF n (%) 5(50) - - -
Anti-CCP n (%) 5(50) - - -
Except where indicated otherwise values are the median (interquartile range).
P- values are calculated by Kruskal-Wallis or Fishers exact test. asignificant
difference between only RA-SpA and SpA-PsA. bsignificant difference between
only RA-SpA. DMARD Disease Modifying Anti-Rheumatic Drug, DAS28-crp Disease
Activity Score 28 –crp, TJC Tender Joint Count, SJC Swollen Joint Count,
BASDAI Bath Ankylosing Spondylitis Disease Activity Index, ASDAS Ankylosing
Spondylitis Disease Activity Score, VAS Visual Analogue Scale, HAQ Health
Assessment Questionnaire, HLA-B27 Human Leucocyte Antigen-B27, IgM-RF
Immunoglobulin M Rheumatoid Factor, Anti-CCP Anti–citrullinated
protein antibodies
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inflammatory arthritis, in contrast to findings for osteo-
arthritis [19]. When focusing on unidimensionality, the
test was satisfactory with all items representing the same
construct ‘neuropathic pain’. DIF was found for different
items for gender, diagnosis and disease activity. However,
the magnitude of DIF contrasts was well below 0.5
logits, and hence had no clinical relevance [34]. This,
together with the fact that the seven items of the PDQ
assess the presence and severity of equally representative
somatosensory symptoms of neuropathic pain, reduces
the overall influence of the observed DIF on the total
score, and it seems unlikely that it represented a threat
to unidimensionality when the PDQ was used for classi-
fication of the construct ‘neuropathic pain’. Though
unproven, there is a perception among some patients
with inflammatory arthritis that warm conditions are
related to symptom relief [43], which could explain the
ranking of item 5 in the item hierarchies and the differ-
ent use of the categories in the rating scale analysis.
The item–person map (Fig. 2) indicated that the PDQ
had targeted items to the examined sample. No ceiling
effect was found indicating that the items relevantly
captured the neuropathic pain symptoms in the sample,
the most severe included [23]. There was an indication
of lack of easier items and subsequent lack of precision
in the lower end of the scale, which may result from the
design of the questionnaire only including items describ-
ing prototypical symptoms of neuropathic pain. With
the exception of the item describing pain course pattern,
no items describe prototypical symptoms of nociceptive
pain, consequently the classification of nociceptive pain
is based on the lack of neuropathic pain symptoms. This,
Table 3 Item fit statistics
Mean square - Z standard deviation
RA PsA SpA All diagnoses
Item Infit Outfit Infit Outfit Infit Outfit Infit Outfit
1 0.82 −2.4 0.8 −2.3 1.04 0.6 1.06 0.7 0.91 −1.1 0.95 −0.5 0.92 −1.7 0.94 −1.2
2 0.93 −0.9 0.86 −1.5 0.72 −3.8 0.67 −3.4 0.84 −2.0 0.79 −1.8 0.84 −3.5 0.80 −3.5
3 1.04 0.5 1.01 0.2 0.99 −.01 0.99 −.01 1.02 0.3 1.01 0.2 1.01 0.2 1.00 0.1
4 1.01 0.2 0.97 −0.3 1.08 1.0 1.02 0.2 1.0 0.0 0.93 −0.6 1.03 0.6 0.97 −0.4
5 1.14 1.7 1.09 1.1 1.09 1.2 1.07 0.9 1.14 1.7 1.11 1.3 1.12 2.5 1.09 1.9
6 1.14 1.7 1.21 1.9 1.24 2.9 1.26 2.4 1.08 1.0 1.12 1.1 1.14 2.9 1.19 2.9
7 0.98 −0.2 0.99 0.0 0.91 −1.2 0.84 −1.8 1.04 0.6 1.05 0.6 0.99 −0.1 1.00 0.0
Critical values for mean squares were calculated based on the sample sizes for the separate diagnosis (infit MnSq = 1.12, outfit MnSq = 1.35, ZSTD < 2) and
overall (infit MnSq =1.06, outfit MnSq S = 1.2, ZSTD < 2) respectively. Item1. Burning sensations; item 2. Tingling or prickling; item 3. Light touching painful; item
4. Sudden pain attacks; item 5. Cold or heat painful; item 6. Numbness; item 7. Slight pressure pain
Fig. 1 Differential item functioning (DIF) plot illustrating different item difficulty across diagnoses
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we consider to be of less importance when the PDQ is
being used to classify neuropathic pain. The indication
of imprecision with regard to the item’s ability to distin-
guish between persons is probably explained by the same
fact that the items are only describing symptoms of one
phenomenon. High item separation was found, which
may result from the very large sample size [23].
In the test-retest study, the ICCs reflected strong to
very strong agreement depending on diagnosis while the
Bland Altman plots showed some differences between
test and re-test. In general the second score was lower
than the initial score, which could be a result of a higher
awareness of pain status, or actual reduction of symp-
toms, though this is not very likely having the short
interval in mind. The PDQ is a classification instrument
and accordingly we evaluated whether the difference in
score that arose when the PDQ was administered repeat-
edly over days affected the classification group (pain
phenotype). Consistent pain classification was obtained
in 70% of participants with RA; 80% of participants with
Table 4 Item difficulty measures causing the different item hierarchies across diagnoses
Item difficulty
RA PsA SpA Across all diagnosis
5. Cold or heat painful (−0.93) 5. Cold or heat painful (−0.85) 5. Cold or heat painful (−0.79) 5. Cold or heat painful (−0.86)
3. Light touching painful (−0.02) 1.Burning sensations (−0.2) 7. Slight pressure pain (−0.32) 7. Slight pressure pain (−0.10)
1.Burning sensations (0.04) 7. Slight pressure pain (−0.05) 1.Burning sensations (−0.13) 1.Burning sensations (−0.10)
6. Numbness (0.04) 3. Light touching painful (0.04) 3. Light touching painful (−0.07) 3. Light touching painful (−0.02)
7. Slight pressure pain (0.06) 6. Numbness (0.08) 6. Numbness (0.00) 6. Numbness (0.04)
2.Tingling or prickling (0.25) 2. Tingling or prickling (0.44) 4. Sudden pain attacks (0.68) 2. Tingling or prickling (0.46)
4. Sudden pain attacks (0.45) 4. Sudden pain attacks (0.50) 2. Tingling or prickling (0.70) 4. Sudden pain attacks (0.54)
The easiest item is the most endorsed item (lowest difficulty measure); the most difficult item is the least endorsed item (highest difficulty measure)
Fig. 2 Item-person map illustrating the threshold distributions. The most difficult items and the person with most severe neuropathic pain are
shown at the left. Each item is shown in three rows representing different rating scale measures. Items; Center: the mean item difficulty calibration.
Bottom: measure level corresponding to a probability of 0.5 of being rated in the lowest category of the rating scale. Top: measure level coresponding
to a probability of 0.5 of being rated in the highest category of the scale
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PsA; 90% of participants with SpA, and 80% of partici-
pants in total. This, in combination with the fact that no
participants changed classification group between non-
neuropathic and neuropathic pain indicated satisfactory
consistency in pain classification.
Strengths and limitations
The inclusion of a large and diverse sample of patients
with inflammatory rheumatic joint disorders was a great
strength of the Rasch analysis. The study sample was
not representative for the general patient population
encountered in daily clinical care, but was chosen to
represent as large a variation as possible to enable
determination of the validity of the PDQ across the
spectra of diagnoses, gender and disease activity. A limi-
tation of the Rasch analysis was that two of the items
were not applicable in the Rasch model [19] due to their
character, though this may have been handled to some
extent by transformation into interval level data, this
was not done as there was no intention to create a scale
for measuring change and others have demonstrated
difficulties in doing so [19]. However, the somatosensory
profiling of pain is based on the seven items subjected to
analyses [14, 44]. It might be questioned whether the cut
off points of the scale validated in patients with various
chronic pain conditions are applicable in patients with
inflammatory arthritis. Ideally, future research should
address the criterion validity and the cut off points of
the PDQ scale by testing it against a clinical ‘gold
standard’. Although this standard currently does not
exist, it could be approached for instance by construct-
ing clinical consensus on signs and symptomatology and
the use and interpretation of quantitative sensory test-
ing, test of descending pain pathways and neuro-
imaging. The test-retest study was based on a priori
power calculations of ICC and was therefore limited by
a somewhat small sample size in relation to classification
consistency. Furthermore, the study sample reflected the
characteristics of the distinct diagnosis and correspond-
ingly differences in baseline characteristics across the
three diagnoses were found. Measurement of C-reactive
protein is included in the disease activity score, and
therefore evaluation of disease activity at retest was not
feasible.
Fig. 3 Bland Altman plots showing the agreement of PDQ scores between test and retest. ‘In total’ refers to the total of all scores across diagnoses.
The square in bold in the diagram showing ‘in total’ represents two patients
Table 5 Distribution of participants in the PDQ categories
according to diagnosis in the test-retest study
n
PDQ score < 13 PDQ score 13–18 PDQ score > 18
Test Retestc Test Retest Test Retest
RA 4 4 3 4 3 2
PsA 4 5 2 2 4 3
SpA 7 7 2 1 1 2
In total 15 16 7 7 8 7
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Conclusion
In conclusion; from the perspective of the Rasch model,
the seven-item version of the PDQ assessing somatosen-
sory symptoms of neuropathic pain based on a six-
category Likert scale, demonstrated sufficient psychometric
properties when applied in a clinical sample of patients
with RA, SpA and PsA. Consistency in pain classification
was strong to very strong. It is therefore suggested that the
PDQ may be used as an easily applied instrument assisting
mechanism-based pain classification and identification of
individuals with a significant central pain component, as
strategies in addition to inflammatory disease suppression
are likely to be required in the management of these
patients.
Due to the observed relative problems with the rating
scale, caution is urged in grading the severity of somato-
sensory symptoms in inflammatory arthritis.
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